RecruitingPHASE1, PHASE2NCT05822908
A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD
Studying Huntington disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Vico Therapeutics B. V.
- Principal Investigator
- Chief Medical OfficerVICO Therapeutics
- Intervention
- VO659(drug)
- Enrollment
- 68 enrolled
- Eligibility
- 25-60 years · All sexes
- Timeline
- 2023 – 2028
Study locations (14)
- Rigshospitalet, Copenhagen, Denmark
- Centre Hospitalier Universitaire dÁngers, Angers, France
- CHU Gui de Chauliac Montpellier- Expert Center of Neurogenetic diseases, Department of Neurology, Montpellier, France
- Universtiry Hospitals Pitie Salpetriere - Charles foix - Paris, Paris, France
- Katholisches Klinikum Bochum, Bochum, Germany
- Deutsches Zentrum fur Neurodegenerative Erkrankungen (DZNE), Bonn, Germany
- Universitatsklinikum Essen - Neurologie, Essen, Germany
- Universitatsklinikum Tübingen, Tübingen, Germany
- Meir Medical Center, Kfar Saba, Israel
- Sourmansky Medical Center, Tel Aviv, Israel
- Leiden University Medical Center LUMC, Leiden, Netherlands
- Radbout University Medical Centre, Nijmegen, Netherlands
- University College London Hospitals NHS Foundation, London, United Kingdom
- John Radcliffe Hospital, Oxford, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05822908 on ClinicalTrials.govOther trials for Huntington disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07513844Optimizing Parameters of Low-Intensity Focused Ultrasound for Pallidal Modulation in Huntington's DiseaseFirst Affiliated Hospital of Fujian Medical University
- ENROLLING BY INVITATIONPHASE2, PHASE3NCT07537075An Extension of SKY-0515 in Participants With Huntington's DiseaseSkyhawk Therapeutics, Inc.
- RECRUITINGPHASE3NCT07326709A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's DiseaseNovartis Pharmaceuticals
- RECRUITINGPHASE1, PHASE2NCT07451613Safety and Tolerability Study of Human Neural Stem Cells for Huntington's DiseaseLeslie Thompson
- RECRUITINGEARLY PHASE1NCT06634628iMagemHTT-009- FIH Evaluation of Novel Mutant Huntingtin PET Radioligand [11C]CHDI-00491009CHDI Foundation, Inc.
- RECRUITINGPHASE2, PHASE3NCT07378644Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's DiseaseSkyhawk Therapeutics, Inc.
- RECRUITINGNCT07253038Evaluation of Three Tests to Assess Social Cognition in Huntington DiseaseRegion Skane
- RECRUITINGNANCT07213648Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)University of Virginia